Manni A, Arafah B M, Pearson O H
Cancer. 1981 Dec 1;48(11):2507-9. doi: 10.1002/1097-0142(19811201)48:11<2507::aid-cncr2820481127>3.0.co;2-e.
Fluoxymesterone (Halotestin), 10 mg p.o. BID, was given to 33 women with Stage IV breast cancer who had previously been treated wih the antiestrogen tamoxifen (Nolvadex) and of whom 17 had also undergone hypophysectomy. Objective remissions were obtained in 13 patients (39%) with an average duration of 11+ months. Response rate to fluoxymesterone was similar in patients who had previously responded to tamoxifen and in those who had failed. Duration of response was longer in the former group (12+ vs. 8 months), but this difference was not statistically significant. Of 17 patients who had been previously treated with tamoxifen and hypophysectomy, seven obtained further remission from fluoxymesterone for an average duration of ten months. Two patients with remissions from fluoxymesterone had previously failed to respond both to antiestrogen therapy and to the removal of the pituitary gland. Androgens appear to be an effective sequential endocrine treatment of Stage IV breast cancer after tamoxifen and hypophysectomy. The mechanism by which androgens induce tumor regression in some patients is probably not an antiestrogenic effect or an indirect effect mediated through the pituitary gland, but perhaps a direct action at the tumor level.
给33名IV期乳腺癌女性患者口服氟甲睾酮（Halotestin），剂量为10毫克，每日两次。这些患者之前接受过抗雌激素药物他莫昔芬（Nolvadex）治疗，其中17人还接受过垂体切除术。13名患者（39%）获得客观缓解，平均缓解持续时间为11个月以上。之前对他莫昔芬有反应的患者和无反应的患者对氟甲睾酮的反应率相似。前一组患者的缓解持续时间更长（12个月以上对8个月），但这种差异无统计学意义。在17名之前接受过他莫昔芬和垂体切除术治疗的患者中，7人从氟甲睾酮治疗中获得进一步缓解，平均缓解持续时间为10个月。两名从氟甲睾酮治疗中获得缓解的患者之前对抗雌激素治疗和垂体切除均无反应。雄激素似乎是他莫昔芬和垂体切除术后IV期乳腺癌有效的序贯内分泌治疗方法。雄激素在一些患者中诱导肿瘤消退的机制可能不是抗雌激素作用或通过垂体介导的间接作用，而可能是在肿瘤水平的直接作用。
